RPL7L1

Across TCGA pan-cancer cohorts, RPL7L1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RPL7L1 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RPL7L1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPL7L1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where RPL7L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.298	0.642	.002	45	view →
HNSC	DFS	Tertile	All	0.185	0.895	.003	32	view →
LSCC	DFS	Quartile	II,III,IV	0.952	0.549	.003	26	view →
CCRCC	DFS	Median	III,IV	0.379	0.733	.002	22	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	20	view →
UCEC	DFS	Quartile	III,IV	1.000	0.301	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPL7L1–PDAC (OS)

Open the PDAC breakdown →